The main mechanism by which arginine supplementation (and by extension, L-Citrulline supplementation) influences blood health is through being the substrate for nitric oxide synthase (NOS) enzymes to produce nitric oxide from, which then signals via soluble cyclic guanylyl receptors to produce cGMP. The production of nitric oxide and subsequent production of intracellular cGMP underlie a good deal of arginine's benefits.
NOS enzymes come in three main isoforms: [78][79] inducible NOS (iNOS), which is created in response to inflammatory stressors, neuronal NOS (nNOS), which was first discovered in neurons and is also at the motor endplates in skeletal muscles, and endothelial NOS (eNOS), which was initially thought to be only in the endothelium but is quite widespread[80] including brain tissue.[48][46]
NOS enzymes work in dimers that are jointed head to head and the catalytic mechanisms is dependent on this dimerization as well as heme, tetrahydrobiopterin, calmodulin, NADPH (as electron donor) and both FMN and FAD.[81][82][83] As such, NOS enzymes (all three isoforms) are NADPH-requiring flavoproteins.[84][85][86] Their structure and function is complex (reviewed here[87]) but there is a basic binding site for arginine and the electrons donated from NADPH cause arginine to convert to citrulline giving off nitric oxide as a byproduct; iNOS exclusively uses and eNOS may also use a free radical intermediate called Nω-hydroxy-L-arginine (L-NOHA), which degrades to citrulline and nitric oxide in the presence of H2O2.[78][88]
Nitric Oxide Synthase (NOS) enzymes use arginine to produce nitric oxide, and nitric oxide (which produces cGMP) is known to mediate a wide variety of actions associated with arginine supplementation. Although arginine supplementation is thought to increase activity of NOS enzymes (by providing more substrate), simply stimulating the activity of these enzymes is also a feasible option to increase nitric oxide
Increased nitric oxide (usually measured by plasma nitrate/nitrite, citrulline, or urinary cGMP concentrations) appears to be increased with L-arginine in persons with essential hypertension,[89] artherothrombosis,[90] and type II diabetes.[91] Studies in otherwise healthy athletes taking L-arginine are quite mixed; there are instances where biomarkers of nitric oxide metabolism are increased[92][92] while other studies fail to note any modification.[93][94][95] Not surprisingly, the benefits associated with nitric oxide do not occur when nitric oxide biomarkers are not increased.
The unreliability of arginine increasing nitric oxide may be due to the physiological concentrations of arginine (40-100µM in extracellular space[96] and possibly reaching up to 800µM intracellularly[97]) being enough to saturate endothelial nitric oxide synthase (eNOS) inherently (Usually stated to be a Km of 3µM[98][99] but at times is measured as high as 29μM[100]). This implies that the enzyme is already at maximal efficacy, and that further supplementation does not increase conversion rate (due to a backlog of arginine in serum); the observations that arginine still increases nitric oxide at times (albeit unreliably) is referred to as the L-arginine paradox.[101][102]
This theory is in line with observations that sometimes nitric oxide metabolism is unaffected despite up to 300% increases in plasma arginine.[95][103]
Arginine is the substrate from which nitric oxide is derived (supplemental citrulline can also increase nitric oxide as a consequence of increased plasma arginine levels), a signaling molecule that mediates an increase in cGMP, leading to a cascade of reactions that lead to vascular relaxation and blood vessel dilation. Importantly, the proposed mechanism for increased production of nitric oxide from an increased level of serum or intracellular arginine levels, is flawed when enzyme kinetics are taken into consideration. Substrate availability (arginine) is not typically a limiting factor (in normal physiological conditions) in the production of nitric oxide. As such, an excess of arginine, achieved through supplementation, would not yield higher levels of nitric oxide.
One study has noted a transient increase in nitric oxide production that appears to be more like that of an agonist than a substrate[104] and later it was found that arginine has the ability to active the α2-adrenergic receptors,[105] which can directly stimulate nitric oxide without requiring converion into citrulline via NOS. However, arginine was fairly weak (outperformed by agmatine)[105] but this mechanism has not been ruled out yet.
Furthermore, extracellular arginine does appear to be a determinate of nitric oxide release[100] (the CAT1 transporter that shuttles arginine is highly associated with eNOS[106] and inhibiting extracellular influx prevents eNOS activation[107]) while intracellular arginine concentration does not appear to be associated.[102] Due to the transport being required but intracellular arginine not being per se required, it is thought that the colocalization of CAT1 with eNOS[106][108] may also play a role in stimulation of eNOS activity.
Theoretically possible that it can directly stimulate nitric oxide independent of being a substrate, but the mechanisms are either not overly potent (α2-adrenergic receptors) or they are currently unexplored in depth (CAT1 transportation)